Duloxetine does not appear to increase the risk of birth defects, but it does carry some risks later in pregnancy, particularly for newborns around the time of delivery. A large nationwide study using data from Denmark and Sweden found no increased risk of major or minor congenital malformations or stillbirths associated with duloxetine exposure during pregnancy. That said, the decision to continue, switch, or stop this medication involves weighing those reassuring findings against real concerns about third-trimester effects and the consequences of leaving depression or anxiety untreated.
Risk of Birth Defects and Stillbirth
The strongest evidence on duloxetine and birth defects comes from a large register-based study covering pregnancies in Denmark and Sweden. When researchers compared duloxetine-exposed pregnancies to matched unexposed pregnancies, the odds ratio for major malformations was 0.98, essentially identical to the baseline population risk. The same study found no increased risk of minor malformations or stillbirth across multiple analytical approaches. Every comparison pointed in the same direction: duloxetine taken during pregnancy does not appear to cause structural birth defects.
Newborn Adaptation Problems in Late Pregnancy
The bigger concern with duloxetine involves what happens when a baby is exposed close to delivery. Like other antidepressants, duloxetine can cause neonatal adaptation syndrome, a temporary set of symptoms that appear in the first days after birth. Affected newborns may show jitteriness, irritability, and breathing difficulties as their bodies adjust to no longer receiving the drug through the placenta.
Duloxetine appears to carry a higher risk of this than many other antidepressants. In a retrospective study comparing individual medications, infants exposed to duloxetine had the highest rates of NICU admissions at 39.6% and adaptation syndromes at 15.1%. When researchers looked specifically at third-trimester exposure, duloxetine was associated with nearly five times the odds of adaptation syndrome compared to unexposed infants. These symptoms are typically short-lived and manageable, but they can mean extra monitoring or a longer hospital stay after delivery.
Postpartum Hemorrhage Risk
Duloxetine taken late in pregnancy is also linked to a modestly higher risk of heavier bleeding after delivery. One large U.S. study found postpartum hemorrhage occurred in 3.5% of women taking duloxetine near delivery compared to 2.3% of unexposed women, a relative risk increase of about 53%. That same study found the risk was also higher compared to women taking SSRIs, suggesting this isn’t just a general antidepressant effect. Duloxetine and the closely related medication venlafaxine both affect a brain chemical called norepinephrine in addition to serotonin, which may play a role in how the uterus contracts after delivery.
How Pregnancy Affects Drug Levels
Your body processes medications differently during pregnancy. Blood volume increases, kidney function speeds up, and liver enzymes that break down drugs become more active. For duloxetine, the limited data available suggests that blood levels may drop significantly as pregnancy progresses. One case showed the concentration-to-dose ratio falling from 1.17 in the first trimester to 0.17 in the second, a dramatic decrease. This means the same dose may become less effective over time, and some women experience a return of depression or anxiety symptoms in later pregnancy. Your prescriber may need to adjust your dose, and levels often need to be reduced again after delivery when your metabolism returns to normal.
What Happens When Depression Goes Untreated
The risks of duloxetine don’t exist in a vacuum. Untreated depression during pregnancy carries its own set of consequences for both mother and baby. Women with untreated depression face higher rates of preterm birth and low birth weight. Their babies are born with elevated levels of the stress hormone cortisol, which raises the child’s own risk of developing depression, anxiety, and behavioral disorders later in life.
There are also indirect effects. Depression makes it harder to maintain good prenatal care, attend appointments, eat well, and avoid harmful substances. A woman who is depressed is more likely to engage in smoking and substance use during pregnancy. For someone whose depression is well-controlled on duloxetine, stopping the medication can trigger a relapse that introduces these risks, sometimes within weeks.
Breastfeeding on Duloxetine
If you’re planning to breastfeed, duloxetine passes into breast milk in very small amounts. Multiple studies have measured the relative infant dose at well under 1% of the mother’s weight-adjusted dose, with estimates ranging from 0.14% to 0.82%. For context, a relative infant dose below 10% is generally considered compatible with breastfeeding. In one infant tested at 32 days of life, duloxetine was completely undetectable in the baby’s blood. In another case, the infant’s plasma level was less than 1% of the mother’s. The available evidence, though limited, suggests that breastfeeding while taking duloxetine exposes the infant to very little of the drug.
FDA Labeling and Pregnancy Registries
Duloxetine does not carry a specific pregnancy risk category under the current FDA labeling system, which replaced the older letter grades (A, B, C, D, X) in 2015. Instead, the label describes available human data, which at this point is reassuring for birth defects but flags neonatal complications with late-pregnancy use. The FDA also maintains a pregnancy exposure registry through the National Pregnancy Registry for Antidepressants, which actively collects data from women who take duloxetine or other antidepressants during pregnancy. If you’re currently pregnant and taking duloxetine, enrolling in this registry (at 1-866-961-2388 or womensmentalhealth.org) contributes data that helps clarify risks for future patients.
Weighing the Decision
The overall picture for duloxetine in pregnancy is more nuanced than a simple safe-or-not answer. First-trimester exposure does not appear to increase birth defect risk. The real trade-offs emerge later: a meaningful chance of short-term newborn complications if taken near delivery, a modest increase in postpartum bleeding, and the possibility of needing dose adjustments as your body’s metabolism shifts. For some women, these risks are worth accepting because the alternative, relapsing into severe depression or anxiety, carries its own serious consequences. For others whose symptoms are mild or who respond well to medications with more safety data (certain SSRIs, for example), switching may make sense.
This is a decision that depends heavily on your specific history: how severe your symptoms are, how many medications you’ve tried, how quickly you’ve relapsed in the past, and how far along you are in pregnancy. The evidence supports having that conversation with full information rather than defaulting to stopping medication out of fear.